Recombinant type-5 vector-based ebola vaccine safe

December 27, 2016

(HealthDay)—For healthy adults from Sierra Leon, the recombinant type-5 vector-based Ebola vaccine is safe and immunogenic, according to a study published online Dec. 21 in The Lancet.

Feng-Cai Zhu, from the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing, China, and colleagues recruited healthy HIV-negative aged 18 to 50 years, with no history of Ebola virus infection and no previous immunization with other Ebola candidate vaccines. Five hundred participants were randomized to receive high-dose (1.6 × 1011 viral particles; 250 participants), low-dose vaccine (8.0 × 1010 viral particles; 125 participants), or (125 participants).

The researchers found that at least one solicited adverse reaction was reported by 53, 48, and 43 percent of in the high-dose, low-dose, and placebo groups, respectively, within seven days of vaccination; most were mild and self-limiting. Vaccine recipients more often had solicited injection-site adverse reactions (26 and 25 percent in the high- and low-dose groups, respectively, versus 17 percent in the placebo group; P = 0.0169). In the low- and high-dose groups, glycoprotein-specific antibody responses were detected from day 14 onward (geometric mean titer, 1,251.0 and 1,728.4, respectively); these peaked at day 28 and decreased rapidly in the following months.

"The recombinant adenovirus type-5 vector-based Ebola vaccine was safe and highly immunogenic in healthy Sierra Leonean adults, and 8.0 × 1010 was the optimal dose," the authors write.

Two authors are employees of Tianjin CanSino Biotechnology, a co-developer of the vaccine.

Explore further: Study examines safety, immune response of candidate Ebola vaccines

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Study examines safety, immune response of candidate Ebola vaccines

April 19, 2016
In a study appearing in the April 19, 2016 issue of JAMA, Matthew D. Snape, F.R.C.P.C.H., M.D., of the University of Oxford, United Kingdom, and colleagues conducted a phase 1 trial to evaluate the tolerability and immunogenicity ...

Two-vaccine Ebola regimen shows promise in early-stage clinical trial

April 19, 2016
An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are described in the April ...

Subunit vaccine efficacious against herpes zoster

April 30, 2015
(HealthDay)—A subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (HZ/su) is efficacious against herpes zoster infection in older adults, according to a study published online ...

Experimental zoster vaccine effective in adults aged 70+

September 15, 2016
(HealthDay)—An experimental vaccine against herpes zoster may offer lasting protection for most older adults who receive it, according to a study published in the Sept. 15 issue of the New England Journal of Medicine.

Recommendations updated for meningococcal vaccine in HIV

November 7, 2016
(HealthDay)—In the Nov. 4 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, new recommendations are presented for meningococcal conjugate vaccination among HIV-infected ...

Final trial results confirm Ebola vaccine provides high protection against disease

December 23, 2016
An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most ...

Recommended for you

Marker may help target treatments for Crohn's patients

October 16, 2018
Crohn's disease (CD), a chronic inflammatory condition of the intestinal tract, has emerged as a global disease, with rates steadily increasing over the last 50 years. Experts have long suspected that CD likely represents ...

Study traces hospital-acquired bloodstream infections to patients' own bodies

October 15, 2018
The most common source of a bloodstream infection acquired during a hospital stay is not a nurse's or doctor's dirty hands, or another patient's sneeze or visitor's cough, but the patient's own gut, Stanford University School ...

Polio: Environmental monitoring will be key as world reaches global eradication

October 15, 2018
Robust environmental monitoring should be used as the world approaches global eradication of polio, say University of Michigan researchers who recently studied the epidemiology of the 2013 silent polio outbreak in Rahat, ...

Researchers make essential imaging tests safer for people at risk of acute kidney injury

October 15, 2018
Every year, millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes. "For the majority of patients, these are safe and necessary procedures. However, about ...

Medical marijuana might help MS patients, but uncertainty remains

October 13, 2018
Medical products derived from marijuana might have a mild benefit in treating symptoms of multiple sclerosis, based on reports from patients.

Do not give decongestants to young children for common cold symptoms, say experts

October 11, 2018
Decongestants should not be given to children under 6—and given with caution in children under 12—as there is no evidence that they alleviate symptoms such as a blocked or runny nose, and their safety is unclear, say ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.